SYNTHECON INC.

Company Snapshot

Founded: 1990
Entity Type: Private
Region: U.S.
Headquarter: Texas, U.S.
Key Geographics: U.S.
Corporate Address: 1100 Hercules Ave, Suite 290 Houston, Texas 77058 U.S. Tel. +1-713-741-2582 www.synthecon.com

Company Overview

Synthecon was founded by a project manager and chief engineer of the NASA Life Sciences Division and Johnson space center joint project whose goal was to examine microgravity conditions during the non-orbit phase of the shuttle missions. With this background, NASA engineers developed a Rotating Wall Vessel (RWV). During ground validation studies, it was found that cells in RWV produced three dimensional spheroids and spontaneously aggregated into tissue-like forms. Co-founders of Synthecon obtained the license from NASA to use the technology (under the trademark Rotary Cell Culture System, or RCCS) for commercial purposes. The company’s products include:

  • Bioreactors systems:
    • Stem cells lines: maintenance, expansion and differentiation.
    • Cancer modeling: tumor spheroid culture.
    • Tissue engineering, spheroid formation and culture.
    • Organoid culture.
    • Hollow organ culture.
    • Modeled microgravity. 
  • Nanobiomatrix scaffold:
    • Nano-scale polymer fibers with similar size and structure as in native extracellular matrix.
    • Sheets, discs, well-plates, tubes.
    • Biostructure matrix scaffolds. The non-woven structure of fibers has provided a better surface than any biomedical textiles.

SYNTHECON INC. In Reports

Laboratory Animal Models, 3D Cultures and Organoids: Global Markets

BCC Research Market Report for Laboratory Animal Models, 3D Cultures and Organoids Market. Global market for organoids is estimated to increase from $1.4 billion in 2022 to reach $3.7 billion by 2027 with a CAGR of...

Single-use Technologies for Biopharmaceuticals: Global Markets

BCC Research Market Report for Single-use Biopharmaceutical’s technologies. Get market applications, such as monoclonal antibodies, vaccines, gene therapy, recombinant proteins, blood derivatives and anticancer drugs....

Single-use Technologies for Biopharmaceuticals: Global Markets

The global single-use technology in the biopharmaceutical market should reach $5.9 billion by 2024 from $3.5 billion in 2019 at a compound annual growth rate of 11.3% for the period of 2019 to 2024.

Company's Business Segments

  • Products : RCCS 3D Cell Culture System, Stem Cell Culture Systems, Perfusion Biorectors
  • Services : Custom-designed bioreactors, Technical Resources and Support

Applications/End User Industries

  • Biotechnology
  • Pharmaceuticals
  • Regenerative Medicine
  • Healthcare
  • Research Institutions
AI Sentiment